crisis has brought the optimal design of pharmaceutical patent policy to the fore. In this paper we evaluate patent policy in … the US pharmaceutical industry. We estimate the effect of patent length and scope on generic entry prior to the expiration … of new drug patents using two quasi-experimental approaches: one based on changes in patent laws and another on the …

Patent settlements between originator and generic firms in the pharmaceutical industry have been challenged by … antitrust and competition authorities in the U.S. and the EU. Particularly settlements with large "reverse payments" to generic … firms raise the concern of collusive behaviour for protecting weak patents and delaying price competition through generic …

general cost of living. This article argues there should be greater competition for the production of follow-on drugs through … the strengthening of the double patenting prohibition: preventing extending exclusive rights beyond the original patent … the inventor in two patents and (2) only applying the prohibition when the earlier patent did not satisfy the technical …

This chapter describes the market for pharmaceuticals, which exceeded $500 million in sales in 2010. The industry is … the application of biotechnology to drug development as well as firms that specialize in low-cost production of off-patent …

Since the patent system relies on private litigation for challenging weak patents, and patent settlements might … influence the incentives for challenging patents, the question arises whether the antitrust assessment of patent settlements … should also consider their impact on the incentives to challenge potentially invalid patents. Patent settlements in the …

generic competition. Specifically, the regulations should be amended to consolidate multiple proceedings into one cause of … action that evaluates patent validity. An economic incentive to challenge weak patents should also be introduced in Canada …. These features encourage competition without deterring pharmaceutical research and development because only patents that are …

hopping, and patent thickets. By increasing generic competition, this legislation would make patients' lives better without …